Posted inCardiology news
Zalunfiban at First Medical Contact for STEMI: Faster Coronary Patency and Better 30‑Day Outcomes but More Minor Bleeding
In an international randomized trial, subcutaneous zalunfiban given at first medical contact improved pre‑PCI infarct‑related artery patency and reduced the likelihood of a worse 30‑day hierarchical clinical outcome versus placebo, with more mild–moderate bleeding but no increase in severe bleeding.